key: cord-0274928-afykd4hu
authors: Ma, Yongping; Shi, Qinlin; Wang, Qiujuan; Chen, Sijing; Gan, Sijie; Fang, Changyin; Shen, Yanxi; Jiang, Min; Lin, Tao; Song, Fangzhou
title: SARS-COV-2 RBD Oral Vaccine Boosted by Mucosal Immune Adjuvant LTB26 via DCs and B Cells Activation in Mice
date: 2021-03-08
journal: bioRxiv
DOI: 10.1101/2020.04.06.025981
sha: 02b8cb322ceb22b7ac22acec9899505efaec763a
doc_id: 274928
cord_uid: afykd4hu

Although several SARS-COV-2 vaccines have been approved, no one oral live vaccine is available. Here, an oral SARS-COV-2 RBD live vaccine containing LTB26 adjuvant has been developed. BALB/c mice are oral vaccinated with attenuated Salmonella typhimurium SL7207 containing pcDNA3.1-LTB26RBD or pcDNA3.1-RBD plasmids. The result shows that the high level of RBD specific antibody is produced in pcDNA3.1- LTB26RBD treatment. The mechanism indicates that LTB26 enhances RBD antibody production by significantly upregulating the activity of MHC II+ DCs and CD19+CD45+ B cells. LTB26 mutant is derived from heat-labile enterotoxin B subunit (LTB) wild type of Escherichia coli with enhanced immune adjuvanticity. Based on the pre-experiment result that SL7207 interferes the function of LTB26, the purified LTB26 was mixed with purified human rotavirus VP8 antigen to explore the mechanism of adjuvant. The results suggests that LTB26 enhances mucosal immune responses via increased of BCR and MHC II+ expression. Furthermore, LTB26 promotes both Th1 and Th2 cell mediated immunity. Therefore, LTB26 maybe a potent adjuvant for mucosal vaccine development in view of the safety of LTB26 than LT toxin.

Since December 2019, the 2019 novel coronavirus (2019-nCoV, SARS-COV-2) has infected over 95.38 million cases worldwide with about 2.03 million deaths. Although about 120 vaccines are in different stage of clinical trials and some inactivated or mRNA vaccine candidates have been approved, little is oral vaccination. Therefore, safe and effective mucosal vaccines are still necessary to prevent infection from SARS-COV-2. (Poland, Ovsyannikova et al., 2020) SARS-COV-2 cell entry depends on ACE2-RBD interaction (Hoffmann, Kleine-Weber et al., 2020) . Therefore, receptor binding domain (RBD) of SARS-COV-2 spike protein (S protein) is the first target for vaccine development. As a pathogen of mucosal infection, mucosal immunity is very important to prevent of SARS-COV-2.

Escherichia coli with enhanced mucosal immune adjuvanticity. From the perspective of clinical application, LTB and its derivatives are safe without toxicity than LT toxin (da Hora, Conceicao et al., 2011) . LT belongs to the members of the AB5 bacterial toxin family and consists of five B subunit (LTB) with a single catalytically active A subunit (LTA) (Merritt, Zhang et al., 2002) . LTA has toxic effects of ADP-ribosylating activity and LTB binds to the cell membrane with GM1 ganglioside (GM1) following delivery LTA into cells inducing infectious diarrhea (da Hora et al., 2011) .

LT has been reported as mucosal immune adjuvant in 1988 (Clemens, Sack et al., 1988) . However, it fails to meet the clinical requirement for its toxicity (da Hora et al., 2011 , Ma, 2016 . Nevertheless, LTB is also not applicable for weaker adjuvanticity comparing with LT. Therefore, the construction of non-toxic LT has been a research hotspot in recent years (Clements & Norton, 2018 , Ghazali-Bina, Pourmand et al., 2019 2016, Nashar, 2014 , White, Haghighi et al., 2017 . However, there is no report to develop adjuvanticity-enhanced LTB mutant.

In this study, we optimized an adjuvanticity-enhanced LTB26 mutant from four LTB mutants (Holmner, Mackenzie et al., 2011 , Ma, 2016 . By fusion expressing with LTB26 adjuvant, a promising live SARS-COV-2 LTB26RBD mucosal vaccine was constructed using attenuated Salmonella typhimurium SL7207 to boost systematic immune responses.

After commercial synthesis of LTB26-RBD and RBD sequences, pcDNA3.1-LTB26RBD and pcDNA3.1-RBD plasmids were constructed, respectively.

Then attenuated Salmonella typhimurium SL7207 (SL7207) was electrically transformed with pcDNA3.1-LTB26RBD, pcDNA3.1-RBD and pcDNA3.1 plasmids at 2.5kv and the restriction enzymes analysis confirmed the recombinants of LTB26-RBD and RBD vaccine candidates 

DCs. In order to decipher the mechanism, dendritic cells (DCs) and B cells from vaccinated mice were purified and analyzed with FCM (flow cytometry). The results suggested that LTB26 activated MCH II + DCs than Salmonella typhimurium SL7207 (SL7207) or RBD alone. The ratio of LTB26RBD to RBD was 29.3 times, LTB26RBD to PBS was 53.1 times, and LTB26RBD to SL7207 was 23.4 times. However, The ratio of SL7207 to PBS was 22.7 times. Even though there were no significant MCH II + DCs differences between SL7207 and SL7207-RBD vaccination mice comparing with SL7207-LTB26RBD treatment. However, SL7207-RBD and SL7207 vaccinations were significantly upregulated DCs than that of PBS treatment (Fig. 1B) . That meant, LTB26 adjuvant was necessary for Salmonella-based vaccine construction. Meanwhile, LTB26 significantly activated CD19 + CD45 + B cells than PBS treatment and increased about 14.5% proportion (Fig. 1C) . As a summary, LTB26 significantly 7 upregulated both DCs and B cells activity to enhance antigen presentation and antibody production.

LTB26 enhanced mice to produce high-level IgG antibody.

After the 3 rd boosting vaccination, BALB/c mice produced high-level RBD specific antibody in SL7207-LTB26RBD immune group (Fig. 2, p<0 .025).

The result indicated that LTB26 has promising adjuvant activity. However, we did not continue the vaccination of SL7207-RBD single group for the absent of LTB26 adjuvant according to the primary test (Fig. 1B, C) .

The characteristic of LTB mutants. The pET32a-LTB, pET32a-LTB26, pET32a-LTB34, pET32a-LTB57 and pET32a-LTB85 were confirmed by sequencing and the products of the five proteins were detected by SDS-PAGE. Then, the proteins were purified using BeaverBeads™ His-tag protein purification kit (Beaverbio, Suzhou, China) and were detected a band of 30 KD protein using SDS-PAGE (Fig.3A) . 3C) . As a summary, the mutations were located in epitope 1(EP1) of LTB (LTB26), middle EP1 and EP2 (LTB34), EP2,3,4 (LTB57) and EP5 (LTB85), respectively ( Fig.3D) (Takahashi, Kiyono et al., 1996) .

immune response. Because Salmonella SL7207 interfered with the adjuvant activity of LTB26 as previously described (Figure 2A ), we used the purified human rotavirus VP8 antigen (hRV VP8 or VP8) to study the 9 molecular mechanism of the adjuvant of purified LTB26 and other mutants.

The serum VP8 specific IgG levels of LTB+VP8, LTB26+VP8 and LTB34+VP8 were significantly higher than that of the VP8 alone group (Fig.4A, p<0 .01). However, the serum IgG level of LTB34+VP8 vaccination was slightly higher than that of LTB+VP8 treatment, but lower than that of LTB26+VP8 vaccination (Fig.4A, p<0 .01). On the contrary, the serum IgG levels of LTB57+VP8 and LTB85+VP8 vaccinations were lower than that of LTB+VP8 groups (Fig. 4A) . Similarly, the variation trends of lung mucosal VP8 specific sIgA were consistent with that of serum IgG among the LTB+VP8 and the other LTB mutants vaccination on 21 d post-vaccination (p<0.001) (Fig. 4B ). LTB26 also elicited the highest mucosal immune response compared with LTB and LTB34, respectively. Thus, LTB26 was the optimal adjuvant mutant of LTB to elicit robust systematic and mucosal immune responses in this study.

The GM1-binding affinity of LTB mutants no positive association with its adjuvant activity. Previous study suggested that LTB adjuvant 10 positively associated with its GM1-binding affinity (de Haan, Verweij et al., 1998 , Holmner et al., 2011 . Thus, the GM1-binding activity of the four LTB mutants was tested in turn. The GM1-binding affinity was decreased gradually from LTB57, LTB26, LTB34, and LTB85 to LTB ( Fig. 4C, D) . However, the adjuvanticity was decreased successively from LTB26, LTB34, LTB, and LTB57 to LTB85. Therefore, LTB26 obtained the highest adjuvanticity with a weaker GM1-binding affinity. Instead, LTB57 had the highest GM1-binding affinity with the lowest adjuvanticity ( Fig. 4C,D) .

pathway and MHC II + DCs. According to GM1-binding analysis and immune data, purified LTB26 and LTB57 were selected as two models of LTB mutant adjuvants to analyze the differential gene expression. Table 1 ).

The Gene ontology (GO) pathway analysis suggested that LTB26 activated several B cell related signal pathways, APC (antigen presenting cell) pathways and MHC II pathway (Fig. 5A) . Instead, LTB57 just upregulated inflammatory related signal pathway (Fig. 5B ). However, LTB preferred to activate inflammatory response, upregulate TNF and IL-10 expression ( Fig. 5C ). The results indicated that LTB26 acted as adjuvant via enhancing MHC II related APCs activation and B cell related signal pathway activation (Fig. 5A) . That was consistent with the result of SL727-LTB26RBD described above ( Fig. 2A, B) . Therefore, the molecular mechanism of LTB26 adjuvant was the same, either by binding the receptor into the cell or by expressing it directly in the cell. 12 Compared with the expression of immune-related cluster of differentiation (CD) genes, the LTB26 upregulated thirteen B cell associated CDs (CD79a, CD79b, CD19, CD22, CD14, CD37, CD38, CD40, CD48, CD52, CD72, CD74 and CD180), one macrophage marker (CD68) and one common lymphocyte marker (D300c2). Among the fifteen upregulated genes, about 86.7% belonged to B cell associated CDs (Table 2 ). Of course, LTB upregulated two T cell (and NK cell) marker (CD2, CD8a), one macrophage marker (CD68) and one monocyte, macrophage and DC common marker (CD14). However, B cell marker was no variation in LTB treatment (Table 2) . Similarly, LTB57 upregulated three T cell associated CDs (CD47, CD63, and CD164), one lymphocyte homing receptor (CD44), one lymphocyte differentiation marker (CD52), one leukocyte marker (CD53), one neutrophils marker (CD177) and one mast cell marker (D300ld3), respectively ( Table 2 ). The T cell related CDs accounted for about 37.5%. However, LTB57 lost the ability of BCR related activation. 13 More importantly, CD79a, CD79b and CD19 were the major component of BCR, which indicated that LTB26 functioned adjuvanticity via BCR pathway. The variation of BCR downstream genes showed that LTB26 upregulated the expression of BCR downstream genes more than 2-fold.

They were following from Syk, Plc-γ, Ras (Rasa3 and Rras), ERKs (Map3k1 or ERK1), Mapk1ip1l (ERK2), Map4k1 (ERK4)) to transcriptional factors Jund and Atf6b (Table 3) 14 Quantitative real-time PCR (q-PCR) verifies the results of transcriptome data. In order to verify the transcriptome data and confirm the above-mentioned APCs, MHC II and BCR pathways, CD8a, CD79a, CD4, IL-1β, IL-4, TNF-α, Jun, Junb, Jund, H2-Ab1, and NFκB1 of PBMC (peripheral blood mononuclear cell) were tested by quantitative real time polymerase chain reaction PCR(q-PCR). The result indicated that ratio of CD4, CD8a, CD79a, IL-4, Jun, H2-Ab1, and NFκB1 were significantly upregulated in LTB26 treatment group compared with LTB and LTB57 treatments, respectively. The increased expression of IL-4 suggested that LTB26 activated Th2 cells response. Meanwhile, the expression of IL-1β, Jund, CD68, TNF-α and Junb were significantly down regulated in LTB26 treatment (Fig. 5D ). The result confirmed the transcriptome analysis that LTB26 activated BCR and MHC II pathways and decreased inflammatory response via downregulation of IL-1β and TNF-α.

IL-10 was also commonly produced in Th2 cells and regarded as an antiinflammatory cytokine and stimulated the proliferation of B cells (Mannino, 15 Zhu et al., 2015, Mocellin, Marincola et al., 2005) . Meanwhile, IFN-γ made Naive CD4 + T cells differentiate to Th1 cells (Zhang, Zhang et al., 2014) .

Therefore, IFN-γ, IL-10 and IL-21were also detected by qPCR. Compared with LTB and LTB57 adjuvant, the LTB26 treatment mice were significantly increased expression of IL-10 and IL-21 in lymphocytes ( As to the proportion of CD3e + NK1. 7A ). Nonetheless, the EI value of LTB26 treatment was higher than that of LTB57.

NLRP3 was one of NOD-like Receptors (NLRs) and played a crucial role in Alum-based adjuvant immune by activating of NLRP3 inflammasome and IL-1β production via MAPK signaling pathway (Sun, Ji et al., 2017) .

However, the expression of NLRP3 in nasal tissue of the purified LTB, LTB26 and LTB57 adjuvant mice was lower than that of in VP8 alone 20 treatment (Fig. 7B, p<0 .01). The result indicated that LTB and its mutants functioned mucosal adjuvant independent on NLRs activation.

The wild type of LTB hit a protein named subunit of heat-labile enterotoxin 3D ) (Guan, Liu et al., 2015 , Takahashi et al., 1996 . Intriguingly, the octapetide (M26S27N28T32I33N34) mutation of LTB26 enhanced the GM1-binding capacity instead. It indicated that the first α-helix of LTB hindered its adjuvanticity, not its amino acid sequences. LTB34 mutation covered three amino acid of the C-terminal of EP1 and three amino acid of the N-terminal of EP2. However, the decapeptide mutation 21 (L35S36L37S38N39S40T41I42N43Y44) of LTB34 were maintained the structure of the second β-sheet and impaired neither GM1-binding affinity nor adjuvanticity (Fig. 3D) . Thus, this fragment was no contribution to both of GM1-binding affinity and adjuvanticity of LTB. The residue of Y39 of LTB was reported to involve in stabilizing the GM1-binding (Holmner et al., 2011 , Ma, 2016 . It was suggested that Y39N mutation did not damage it stabilizing effect.

Instead, the LTB57 mutant maintained the structure of the third β-sheet similar to LTB, however, the amino acids mutation led to lose its adjuvanticity. This mutation (F57Y58E60F61H62H63) was located in the central of epitope EP3 (48-63) and EP4 (54-69) and significantly impaired the adjuvanticity (Fig. 3D ) (Guan et al., 2015) . However, it was separated two residues from the downstream of the typical GM1-binding residue of G33 (numbered G54 in this study) (Fig.3B , C, D) (Ma, 2016 , Nashar, Webb et al., 1996 , Turcanu, Hirst et al., 2002 . Similarly, LTB85 (86-91 aa) mutation was also located in the central T-and B-cell epitope EP5 and 22 retained the second α-helix of LTB (Guan et al., 2015 , Ma, 2016 . Even though the K91 of LTB57 (K91H) was a conserved GM1-binding residue, the hexapetide mutation (Y86V87E88F89H90H91) was not impaired the GM1 affinity, too (Holmner et al., 2011 , Ma, 2016 . However, both LTB57

and LTB85 lost their adjuvanticity for destroying the sequences of T-and B-cell epitope of LTB (Fig.3C, D) . Therefore, the sequences of epitopes of EP3, EP4 and EP5 were important than that of 3D structures for maintaining the adjuvanticity of LTB.

COVID-19 was the most dangerous infectious disease to threat public health since December 2019 causing more than 89 million cases infection with more than 2.1 million death to date (Harrison, Lin et al., 2020) .

Vaccines could help prevent the spread of COVID-19 and end this pandemic. Since on Dec. 18, 2020, FDA had approved two COVID-19

vaccines, several vaccines have been approved and vaccinated in many countries. However, the constant mutation of SARS-COV-2 was not only 23 challenged the effectiveness of the vaccine, but also increased its infectivity (Chen, Wang et al., 2020 , Plante, Liu et al., 2020 Other mutants with K417N or E484K were found in South Africa. 24 Therefore, it remained to be monitored whether the current vaccines would be effective against these mutants in the future. Therefore, the battle against COVID-19 would continue for some time because of insufficient supplies of vaccines. However, RBD was still the effective antigen for vaccine development. We, based on this, developed an attenuated Salmonella typhimurium-based RBD oral vaccine fusing LTB26 as mucosal adjuvant. Then the RBD mutants' vaccine will be constructed on the basis of it in the future.

Salmonella ssp was broadly used as oral vaccine delivery (Yurina, 2018) .

Attenuated Salmonella typhimurium was the most widely used vectors. It was suitable for oral immunization and boosted both mucosal and systemic immune responses (Yurina, 2018) . Therefore, as a mucosal infectious pathogen, Salmonella-based oral vaccine was suitable for SARS-COV-2 prevention. Another advantage of Salmonella-based oral vaccine was that the recombination delivery vehicle was easy to construct. Meanwhile, Salmonella-based oral vaccine was essentially DNA vaccine and the 25 antigenicity of RBD was same as the production of infectious SARS-COV-2 spike protein. Although Salmonella-derived PAMPs (pathogenassociated molecular patterns) has adjuvant activity, we found that its adjuvanticity was weaker than LTB26 (Fig. 2) (Bivona, Cerny et al., 2016) .

Therefore, we designed LTB26RBD fusion gene to enhance the immune response in this study.

Mucosal immunity was one of the important ways to protect the body from the mucosal invading pathogens (Lycke, 2012 , Ma, 2016 , Perez-Lopez, Behnsen et al., 2016 . However, mucosal adjuvant research lagged behind vaccine development and resulted in vaccines failure in some case (Atmar & Keitel, 2009 , Young, Sadarangani et al., 2015 . Therefore, it was also important to develop safe and high effective mucosal adjuvants to enhance the effectiveness of mucosal vaccines. However，GM1 binding sites also existed in other epitopes of LTB such as 51E, Ile58, 58I and 91K (Holmner et al., 2011) . Therefore, we had mentioned that beyond GM1-binding, G33 of LTB was a crucial antigenic determinant residue located in the B-and T-cell epitope region (residue S26 to G45) (Ma, 2016) . Scientist supposed that G33 residue was crucial for the binding affinity of LTB to GM1 and LTB (G33D) mutant lost its GM1-binding affinity and oral immune adjuvant activity (Nashar et al., 1996) . 27 Even so, we had deduced that LTB (G33D) destroyed the function of the key residue of LTB antigenic determinant (residue S26 to G45) rather than the GM1-binding affinity (Ma, 2016) . Therefore, the integrity of LTB epitope was more important than the GM1-binding affinity (Ma, 2016) .

This hypothesis has been verified that LTB57 (57-63 aa) mutation (F57Y58E60F61H62H63) was located in the central T-and B-cell epitope and significantly impaired the adjuvanticity (Fig.3D ) (Ma, 2016 , Nashar et al., 1996 , Turcanu et al., 2002 . Intriguingly, the octapetide (M26S27 N28--T32I33N34) mutation in LTB26 was not only impaired the GM1 affinity, but also enhanced the GM1-binding capacity. Similarly, LTB85 (86-91 aa) mutation was also located in the central T-and B-cell epitope (Ma, 2016) , and this hexapetide (Y86V87E88F89H90H91) mutation was not impaired the GM1 affinity, too. Even though the K91 of LTB57 (K91H) was a conserved GM1-binding residue (Holmner et al., 2011 , Ma, 2016 .

However, both LTB57 and LTB85 lost their adjuvanticity for destroying the structure of T-and B-cell epitope of LTB (Fig.3D) . Therefore, the 28 highlight of this work suggested that the adjuvanticity of LTB was not positively associated with GM1-binding affinity.

Adjuvant stimulated APCs and targeted the innate immune system to induce a robust immune response. In principle, adjuvant could induce hostderived damage-associated molecular patterns (DAMPs) or recognizing PAMPs to enhance antigen-specific immune responses via APCs (DCs) or macrophages (Hayashi, Momota et al., 2018) . DCs sensed and phagocytized invading pathogens and activated naï ve T cells. Then they acted as a major link between innate and acquired immunity to determine the polarization of T cell responses into different effector subtypes (Tesfaye, Gudjonsson et al., 2019) (Steinman & Hemmi, 2006) .

Cytokines were important immune regulators. Purified LTB26 was capable of orchestrating upregulated IL-4, IL-10 and IL-21 expression, significantly, compared with LTB and LTB57 (Fig. 5D, 5E, 5F ). Generally, B cells and CD8 + T cells were the responders to IL-21 by IL-21R (Sondergaard & Skak, 2009 ). CD4 + T cells were main producers of IL-29 21, while TCR stimulation increased CD4 + T cell expression of IL-21R as a positive feedback. IL-10 stimulated cytotoxicity of CD8 + T cells and IFN-γ expression (Oft, 2014) .

IL-4 promoted humoral immunity and IFN-γ promoted cell-mediated immunity (El-Sissi, Mohamed et al., 2020) .

significantly upregulated the expression of IFN-γ and TNF-α compared with VP8 alone treatment, but there were no differentiation among LTB, LTB26 and LTB57 (Fig. 5G) . Thus, purified LTB26 promoted both Th1 and Th2 cells mediated immunity via upregulating IL-4 and IFN-γ expression, which was different from Alum-based vaccine (IL-4 only).

This consistent with the data obtained from FCM and transcriptome analysis.

Together our data indicated that LTB26 adjuvant fused with SARS-COV-2 RBD or purified and mixed with hRV VP8 significantly increased the proportion of MHC II + DCs and CD19 + CD45 + B cells in peripheral blood, which indicated that LTB26 enhanced the processing of vaccine (antigen) 30 via DCs activation and the producing of antibody by B cell activation (Fig   1, 6) . We found Salmonella typhimurium SL7207 was not an ideal vehicle for oral vaccine development for its toxicity. In this study, the BALB/c mice and SD rats were died within 24 h after intraperitoneally injection with the same dose of oral vaccination SL7207 (data not show). Therefore, the less toxicity Salmonella strain or other vehicles were necessary in future research. Furthermore, the mucosal responses of SL7207-LTB26RBD will be performed as a single topic in the future. All the samples were treated as previously described (Liu et al., 2016) . The antibodies were analyzed with horseradish peroxidase (HRP)-labeled goat anti-mice IgG and goat anti-mice IgA (1.0 μg/ml, Boster, Wuhan, China) by ELISA, respectively, as previously described (Liu et al., 2016) . SARS-CoV-2 RBD-His protein was purchased from Nanjing Okay Biotechnology Co., Ltd (Nanjing, China, cat#K1516). Endpoint titers were determined as the dilution of each sample showing a 2.1-fold higher absorbance level of 450 nm as compared to that of the negative control samples. Average OD 450 values for the animals were calculated.

LTB mutants design. Full-length LTB DNA was cloned from EC44815 strain and constructed pET32a-LTB plasmid as our previously report (Ma et al., 2012) . The four LTB mutants were designed to mutate some amino acids located in the B-and T-cell epitope region (Ma, 2016) . The amino acid was numbered from the first M (Met) of signal peptide in LTB. The four LTB mutants were also constructed into plasmid pET32 at BamH I /Sal I site, respectively. Full-length of hRV VP8 DNA (GenBank: L34161) was commercially synthesized (Sangon, Shanghai, China) and inserted into plasmid pET32 at BamH I/Sal I site. The recombinants of pET32-LTB, pET32-LTB26, pET32-LTB34, pET32-LTB57, pET32-LTB85 and pET32-VP8 were expressed in E. coli BL21 cells and purified with BeaverBeads™ His-tag protein purification kits (Beaver, Suzhou, China, cat#70501-5). The endotoxin was removed using ToxinEraserTM resin (Genscript, Nanjing, China, cat#L00338) and the protein concentration 35 was measured by BCA protein assay kit (TaKaRa, Dalian, China, cat#T9300A) as previous described (Ma et al., 2012) .

Animal and Immunization. Six groups of BALB/c mice (3-4 weeks old, male, n=6) were nasal vaccinated with human rotavirus VP8 (VP8), LTB+VP8, LTB26+VP8, LTB34+VP8, LTB57+VP8, LTB85+VP8, and 20 μl PBS, respectively, after anesthetizing with chloral hydrate (0.5 mL/100 g). The VP8, LTB and four LTB mutants were each added 10 μg/mouse respectively. The mice were intranasal boosted twice on 7, and 14 day with same method after first vaccination. All surgery was performed under sodium pentobarbital anesthesia, and euthanized by cervical dislocation. Then immune assay was performed as described above to detect the VP8 specific antibodies from blood, fecal and bronchial mucosal washing, respectively. The PBMCs FCM analysis was performed as previous described.

GM1-binding analysis. The GM1-binding affinity of LTB and its four mutants were determined using GM1-ELLSA (enzyme-linked 36 immunosorbent assay) assay (Minke, Roach et al., 1999) . Immunohistochemistry. Spleen played an important role for lymphocyte 39 migration and immune response after receiving antigen stimulation.

Therefore, CD4, CD11b, and CD45 of splenic lymphocyte were tested after 24h poster vaccination. Haematoxylin and eosin staining and antibody labeling were performed on 4-μm tissue sections as described previously (Liu et al., 2016) . Antibodies(rabbit) against CD11b, CD45 and CD4 were incubated overnight at 4 ℃ . Antibodies (goat) against IgG (rabbit) were used for labeling for 2 h at room temperature. Images of histology and immunohistochemistry were taken with a Nikon Eclipse E600 and Nikon DS-Ri1 camera or with a Digital Slide Scanner (20 × magnification).

The expressions of CD11b, CD45 and CD4 were quantified using a visual grading system based on the extent of staining as previously described (Marechal, Demetter et al., 2009) . Briefly, percentage of positive spleen cells (extent of staining) was graded on scale from 0 to 3: 0, none;

1, 1-30%; 2, 31-60%; 3, 41-60%. The intensity of staining was graded on a scale of 0-3: 0, none; 1, weak staining; 2, moderate staining; 3, strong 40 staining. The combination of extent (E) and intensity (I) of staining was obtained by the product of E times I called EI varying from 0 to 9 for each spot. For statistical analysis, EI score of 0-3 were considered low expression and EI score >3 were considered high expression.

In order to understand the enhanced adjuvanticity of LTB26, the three- Arrow showed the first α-helix.

Adjuvants for pandemic influenza vaccines

Attenuated Salmonella sp. as a DNA Delivery System for Trypanosoma cruzi Antigens

Cross-protection by B subunit-whole cell 42 cholera vaccine against diarrhea associated with heat-labile toxin-producing enterotoxigenic Escherichia coli: results of a large-scale field trial

The Mucosal Vaccine Adjuvant LT

Parenteral adjuvant potential of recombinant B subunit of Escherichia coli heat-labile enterotoxin

Non-toxic derivatives of LT as potent adjuvants

Role of GM1 binding in the mucosal immunogenicity and adjuvant activity of the Escherichia coli heat-labile enterotoxin and its B subunit

F4/80 as a Major Macrophage Marker: The Case of the Peritoneum and Spleen. Results and problems in cell differentiation

Chitosan and chitosan nanoparticles as adjuvant in local Rift Valley Fever inactivated vaccine

Vaccine potential of LenA and LcpA proteins of Leptospira interrogans in combination with Escherichia coli heat-labile enterotoxin, B subunit (LTB)

Adaptation of SARS-CoV-2 in BALB/c mice for testing vaccine efficacy

Analysis and application of a neutralizing linear epitope on liable toxin B of enterotoxin Escherichia coli

Mechanisms of SARS-CoV-2 Transmission and Pathogenesis

DAMP-Inducing Adjuvant and PAMP Adjuvants Parallelly

Enhance Protective Type-2 and Type-1 Immune Responses to Influenza Split Vaccination

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Crystal structures exploring the origins of the broader specificity of escherichia coli heat-labile enterotoxin compared to cholera toxin

Quantitative Proteomic Analysis of Escherichia coli Heat-Labile Toxin B Subunit (LTB) with Enterovirus 71 (EV71) Subunit VP1

Exploring the genomic and proteomic variations of SARS-CoV-2 spike glycoprotein: A computational biology approach. Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases

Recent progress in mucosal vaccine development: potential and limitations

Recent advances in nontoxic Escherichia coli heat-labile toxin and its derivative adjuvants

Construction of Bifidobacterium infantis as a live oral vaccine that expresses antigens of the major fimbrial subunit (CfaB) and the B subunit of heat-labile enterotoxin (LTB) from enterotoxigenic Escherichia coli

The paradoxical role of IL-10 in immunity and cancer

High expression of CXCR4 may predict poor survival in resected pancreatic adenocarcinoma

Characterization and crystal structure of a high-affinity pentavalent receptor-binding inhibitor for cholera toxin and E. coli heat-labile enterotoxin

Structure-based exploration of the ganglioside GM1 binding sites of Escherichia coli heat-labile enterotoxin and cholera toxin for the discovery of receptor antagonists

Interleukin-10 and the immune response against cancer: a counterpoint

The Quest for an HIV-1 Vaccine Adjuvant: Bacterial Toxins as New Potential Platforms

Potent immunogenicity of the B subunits of Escherichia coli heat-labile enterotoxin: receptor binding is essential and induces differential modulation of lymphocyte subsets

IL-10: master switch from tumor-promoting inflammation to antitumor immunity

Mucosal immunity to pathogenic intestinal bacteria

Spike mutation D614G alters SARS-CoV-2 fitness

Vaccine Development: Current Status

IL-21: roles in immunopathology and cancer therapy

Dendritic cells: translating innate to adaptive immunity

Enhanced Immune Adjuvant Activity of Aluminum Oxyhydroxide Nanorods through Cationic Surface Functionalization

Epitope maps of the Escherichia coli heat-labile toxin B 45

Regulation of the germinal center and humoral immunity by interleukin-21

Dendritic Cells to Fine-Tune Antibody Responses

Modulation of human monocytes by

Escherichia coli heat-labile enterotoxin B-subunit; altered cytokine production and its functional consequences

Preformulation studies with the Escherichia coli double mutant heat-labile toxin adjuvant for use in an oral vaccine

The avian influenza vaccine Emerflu. Why did it fail?

Live Bacterial Vectors-A Promising DNA Vaccine Delivery System

TH1/TH2 cell differentiation and molecular signals

The work was funded by a research grant from the National Natural Science Foundation of China (NSFC no. 30972585); We thank professor Shengyong Yang (Chongqing Medical University) proofread the manuscript and gave some constructive advises.

Y.M. conceived of the paper; Q.S. and Q.W. contributed equally and performed main experiments; S.C., S.G. and C.F. performed some experiments; Y.M., Q.S., F.S. and T.L. contributed to write the paper.

No competing interests.